secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2025-12-19T23:59:59+00:00
Accession:  0001104659-25-123305
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure enters ATM agreement for up to $14.5M common stock offering with H.C. Wainwright
--------------------------------------------------------------------------------

- ATM agreement allows sale of up to $14.5M of common stock at market prices, effective December 19, 2025.
- Agent H.C. Wainwright receives 3.0% compensation on gross proceeds from shares sold.
- Net proceeds to fund general corporate purposes, including preclinical studies and clinical trials.
- Sales may be made on Nasdaq or in negotiated transactions; no minimum price or volume commitments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465925123305/0001104659-25-123305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465925123305/tm2533962d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-123305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer